Jennifer A. Low

9.6k total citations · 5 hit papers
74 papers, 7.2k citations indexed

About

Jennifer A. Low is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jennifer A. Low has authored 74 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 38 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Jennifer A. Low's work include Hedgehog Signaling Pathway Studies (24 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer-related Molecular Pathways (11 papers). Jennifer A. Low is often cited by papers focused on Hedgehog Signaling Pathway Studies (24 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer-related Molecular Pathways (11 papers). Jennifer A. Low collaborates with scholars based in United States, United Kingdom and Belgium. Jennifer A. Low's co-authors include Charles M. Rudin, Frédéric J. de Sauvage, Robert L. Yauch, Christine L. Hann, Patricia LoRusso, Daniel D. Von Hoff, Josina C. Reddy, Richard Graham, Howard Mackey and Kapila Ratnam and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Jennifer A. Low

69 papers receiving 7.0k citations

Hit Papers

Efficacy and Safety of Vismodegib in Advanced Basal-Cell ... 2009 2026 2014 2020 2012 2009 2009 2009 2015 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
    2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
  2. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
    2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. New England Journal of Medicine profile →
  3. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
    2009 761 citations Charles M. Rudin, Christine L. Hann et al. New England Journal of Medicine profile →
  4. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
    2009 670 citations Robert L. Yauch, Gerrit J.P. Dijkgraaf et al. Science profile →
  5. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
    2015 302 citations Robert C. Doebele, Lara E. Davis et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer A. Low United States 30 5.0k 2.9k 1.1k 1.0k 961 74 7.2k
Raoul Tibes United States 34 3.6k 0.7× 1.5k 0.5× 488 0.5× 337 0.3× 576 0.6× 144 5.3k
Stephen E. Gould United States 26 4.0k 0.8× 1.8k 0.6× 298 0.3× 202 0.2× 413 0.4× 48 5.3k
Caterina Marchiò Italy 42 2.2k 0.4× 2.9k 1.0× 420 0.4× 477 0.5× 2.4k 2.5× 163 5.8k
David Hogg Canada 40 3.3k 0.7× 4.0k 1.3× 301 0.3× 206 0.2× 726 0.8× 124 6.3k
Giovanni Tonon Italy 42 4.5k 0.9× 2.4k 0.8× 1.0k 1.0× 77 0.1× 1.4k 1.5× 110 7.4k
Hans‐Peter Sinn Germany 47 2.9k 0.6× 3.4k 1.2× 329 0.3× 281 0.3× 3.3k 3.4× 260 8.3k
Pascal Finetti France 52 4.7k 0.9× 4.9k 1.7× 340 0.3× 141 0.1× 3.5k 3.6× 175 9.8k
James C. Marsters United States 23 3.0k 0.6× 1.1k 0.4× 336 0.3× 257 0.3× 317 0.3× 37 3.9k
Johannes L. Peterse Netherlands 50 2.9k 0.6× 4.9k 1.7× 341 0.3× 688 0.7× 4.8k 5.0× 97 9.9k
Jordi Rodón United States 48 5.8k 1.2× 4.1k 1.4× 518 0.5× 126 0.1× 2.3k 2.4× 402 10.2k

Countries citing papers authored by Jennifer A. Low

Since Specialization
Citations

This map shows the geographic impact of Jennifer A. Low's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer A. Low with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer A. Low more than expected).

Fields of papers citing papers by Jennifer A. Low

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer A. Low. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer A. Low. The network helps show where Jennifer A. Low may publish in the future.

Co-authorship network of co-authors of Jennifer A. Low

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer A. Low. A scholar is included among the top collaborators of Jennifer A. Low based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer A. Low. Jennifer A. Low is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Low, Jennifer A., Ray W. Fuller, Irina Gitlin, et al.. (2025). Safety and Tolerability of a Novel Inhaled Thiol-Saccharide Mucolytic (Fexlamose, MUC-031) in Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A4050–A4050.
2.
Doebele, Robert C., Lara E. Davis, Aria Vaishnavi, et al.. (2015). An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discovery. 5(10). 1049–1057. 302 indexed citations breakdown →
3.
Brandhuber, Barbara J., Nisha Nanda, Julia Haas, et al.. (2015). Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers. Molecular Cancer Therapeutics. 14(12_Supplement_2). B192–B192. 5 indexed citations
4.
Hong, David S., Marcia S. Brose, Robert C. Doebele, et al.. (2015). Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Molecular Cancer Therapeutics. 14(12_Supplement_2). PR13–PR13. 12 indexed citations
5.
Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →
6.
Berlin, Jordan, Johanna C. Bendell, Lowell L. Hart, et al.. (2012). A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research. 19(1). 258–267. 143 indexed citations
7.
LoRusso, Patricia, Sarina A. Piha‐Paul, Monica Mita, et al.. (2012). Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential. Cancer Chemotherapy and Pharmacology. 71(1). 193–202. 17 indexed citations
8.
Graham, Richard, Bert L. Lum, Sravanthi Cheeti, et al.. (2011). Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research. 17(8). 2512–2520. 97 indexed citations
9.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782. 74 indexed citations
10.
LoRusso, Patricia, Charles M. Rudin, Josina C. Reddy, et al.. (2011). Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(8). 2502–2511. 420 indexed citations
11.
Caro, Ivor & Jennifer A. Low. (2010). The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment. Clinical Cancer Research. 16(13). 3335–3339. 88 indexed citations
12.
Yauch, Robert L., Gerrit J.P. Dijkgraaf, Bruno Alicke, et al.. (2009). Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science. 326(5952). 572–574. 670 indexed citations breakdown →
13.
Ji, Jay, Ravithat Putvatana, Yiping Zhang, et al.. (2007). A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage. Cancer Research. 67. 4027–4027. 1 indexed citations
14.
Rubinstein, Larry, S. M. Steinberg, Shivaani Kummar, et al.. (2007). Statistical considerations for a phase 0 trial. Journal of Clinical Oncology. 25(18_suppl). 14038–14038. 1 indexed citations
15.
Lewis, Cristina & Jennifer A. Low. (2007). Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.. PubMed. 8(12). 1051–6. 14 indexed citations
16.
Wedam, Suparna, Jennifer A. Low, Xiao‐Sheng Yang, et al.. (2004). A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. Journal of Clinical Oncology. 22(14_suppl). 578–578. 4 indexed citations
17.
Leonard, Gregory D., Jennifer A. Low, Arlene Berman, & Sandra M. Swain. (2004). CA 125 Elevation in Breast Cancer: A Case Report and Review of the Literature. The Breast Journal. 10(2). 146–149. 21 indexed citations
18.
Low, Jennifer A. & Mason Schoenfeldt. (2004). Clinical trials referral resource. Current clinical trials investigating 3-AP.. PubMed. 18(3). 1147, 1149–50. 1 indexed citations
19.
Low, Jennifer A.. (1998). Surface and Interiority: Self-Creation in Margaret Cavendish's the Claspe. Philological quarterly. 77(2). 149–25.
20.
Ehsani, Ali A., Jennifer A. Low, R. Bruce Wallace, & Anna M. Wu. (1993). Characterization of a New Allele of the Human ERBB2 Gene by Allele-Specific Competition Hybridization. Genomics. 15(2). 426–429. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raoul Tibes Breakdown of academic impact, for papers by Stephen E. Gould Breakdown of academic impact, for papers by Caterina Marchiò Breakdown of academic impact, for papers by David Hogg Breakdown of academic impact, for papers by Giovanni Tonon Breakdown of academic impact, for papers by Hans‐Peter Sinn Breakdown of academic impact, for papers by Pascal Finetti Breakdown of academic impact, for papers by James C. Marsters Breakdown of academic impact, for papers by Johannes L. Peterse Breakdown of academic impact, for papers by Jordi Rodón
Rankless by CCL
2026